Related references
Note: Only part of the references are listed.Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody
Shijin Yuan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
Shun Lu et al.
LUNG CANCER (2021)
Associations between absolute neutrophil count and lymphocyte-predominant breast cancer
Chang Ik Yoon et al.
BREAST (2020)
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)
J. Nicholas Bodor et al.
CANCER (2020)
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Romain-David Seban et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Prognostic Values of LDH and CRP in Cervical Cancer
Han Wang et al.
ONCOTARGETS AND THERAPY (2020)
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy
Arsela Prelaj et al.
CLINICAL LUNG CANCER (2020)
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
Karim Amrane et al.
CANCER MEDICINE (2020)
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
Romain-David Seban et al.
CANCERS (2020)
Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy
Kazuki Takada et al.
LUNG CANCER (2020)
Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors
Muhammad Z. Afzal et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors
Tao Jiang et al.
LUNG CANCER (2019)
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
Florian R. Greten et al.
IMMUNITY (2019)
C-reactive protein is a significant predictor of improved survival in patients with advanced non-small cell lung cancer
Xiaoguang Xiao et al.
MEDICINE (2019)
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer
Dickran Kazandjian et al.
JAMA ONCOLOGY (2019)
Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis
Zimu Wang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Inflammatory prognostic biomarkers in advanced non-small cell lung cancer
D. Machado et al.
PULMONOLOGY (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
17P Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients
F Blanc-Durand et al.
ANNALS OF ONCOLOGY (2019)
Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer
Wungki Park et al.
CLINICAL LUNG CANCER (2019)
Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: A systematic review and meta-analysis
Shiqiang Su et al.
INTERNATIONAL JOURNAL OF SURGERY (2019)
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
E. E. Vokes et al.
ANNALS OF ONCOLOGY (2018)
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer
Eric C. Ko et al.
CLINICAL CANCER RESEARCH (2018)
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
Alessandro Russo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
Danielle Benedict Sacdalan et al.
ONCOTARGETS AND THERAPY (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer A meta-analysis
Junwu Duan et al.
MEDICINE (2018)
Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
Aixa E. Soyano et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer
Gema Bruixola et al.
ESMO OPEN (2018)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis
Oezge Canli et al.
CANCER CELL (2017)
Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers
Ana I. Robles et al.
GASTROENTEROLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour
J. K. Pine et al.
BRITISH JOURNAL OF CANCER (2015)
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
M. J. Proctor et al.
BRITISH JOURNAL OF CANCER (2012)
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer
S. Cedres et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials
Peter M. Rothwell et al.
LANCET (2012)
How to obtain the confidence interval from a P value
Douglas G. Altman et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Share Paper
